Word: synthelabo
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...want to work more to do so. And consider the blatant interventionist. Sarkozy brokered the €2 billion state bailout of engineering giant Alstom, angering E.U. members who called it an unfair protectionist subsidy. He also coerced Franco-German pharmaceutical giant Aventis into merging with French competitor Sanofi-Synthelabo, neither of which is state-owned, to thwart takeover plans by Swiss rival Novartis. "I'm conservative, liberal-inclined and I believe in market economics," Sarkozy says. "But when an issue lands on my desk, I don't spend time wondering what [David] Ricardo, Adam Smith or [Friedrich] Hayek would have...
...French are very territorial when it comes to champagne, ski resorts and, yes, pharmaceutical companies, which helps explain why the government strong-armed Sanofi-Synthelabo into sweetening a hostile bid for the Strasbourg-based Aventis--to create a French "national champion" in the pill market--and why the government warned Swiss drugmaker Novartis to stop fishing in the Rhine. Sanofi-Aventis will be the world's third largest pharmaceutical firm, after Pfizer and GlaxoSmithKline. But since the merger announcement, Sanofi's shares have tumbled, in part because investors think $66 billion is too high a price for Aventis, whose...
...absorb the mood elevator called serotonin. Competing ssris (selective serotonin reuptake inhibitors), as they're called, include Lilly's duloxetine and Solvay Pharmaceuticals' fluvoxamine. Both drugs affect the same biochemical pathways, only with greater precision and fewer side effects. But better ssris aren't the only new approach. Sanofi-Synthelabo is looking into the potential of a so-called mao (monoamine oxidase) inhibitor called befloxatone. Monoamine oxidase is another serotonin-disrupting enzyme, so anything that inhibits it should make more of the mood-elevating chemical available to the brain cells...
| 1 |